Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Hims & Hers Health, Inc., Amneal Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc.

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson’s disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Latest Health Care Providers & Services and Hims & Hers Health, Inc., Amneal Pharmaceuticals, Inc. Stock News

As of July 31, 2026, Hims & Hers Health, Inc. had a $6.4 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. Hims & Hers Health, Inc.’s stock is down 14.5% in 2026, down 1.1% in the previous five trading days and down 57.62% in the past year.

Currently, Hims & Hers Health, Inc. does not have a price-earnings ratio. Hims & Hers Health, Inc.’s trailing 12-month revenue is $2.4 billion with a -0.6% net profit margin. Year-over-year quarterly sales growth most recently was 3.8%. Analysts expect adjusted earnings to reach $-0.500 per share for the current fiscal year. Hims & Hers Health, Inc. does not currently pay a dividend.

As of July 31, 2026, Amneal Pharmaceuticals, Inc. had a $5.8 billion market cap, putting it in the 70th percentile of all stocks. Amneal Pharmaceuticals, Inc.’s stock is up 45.4% in 2026, up 2.2% in the previous five trading days and up 127.01% in the past year.

Currently, Amneal Pharmaceuticals, Inc.’s price-earnings ratio is 49.4. Amneal Pharmaceuticals, Inc.’s trailing 12-month revenue is $3.0 billion with a 5.0% net profit margin. Year-over-year quarterly sales growth most recently was 3.9%. Analysts expect adjusted earnings to reach $0.993 per share for the current fiscal year. Amneal Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Hims & Hers Health, Inc.	HIMS	F
Amneal Pharmaceuticals, Inc.	AMRX	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Hims & Hers Health, Inc. has a Value Score of 8, which is Ultra Expensive. Amneal Pharmaceuticals, Inc. has a Value Score of 36, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Hims & Hers Health, Inc., Amneal Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Hims & Hers Health, Inc., Amneal Pharmaceuticals or Inc. is the better investment when it comes to value.

Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
Hims & Hers Health, Inc.	HIMS	D
Amneal Pharmaceuticals, Inc.	AMRX	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Hims & Hers Health, Inc. has a Growth Score of 37, which is Weak. Amneal Pharmaceuticals, Inc. has a Growth Score of 100, which is Very Strong.

The Growth Grade Winner: Amneal Pharmaceuticals, Inc.

As you can clearly see from the Growth Grade breakdown above, Amneal Pharmaceuticals, Inc. has a more attractive growth grade than Hims & Hers Health, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Hims & Hers Health, Inc.	HIMS	C
Amneal Pharmaceuticals, Inc.	AMRX	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Hims & Hers Health, Inc. has a Quality Score of 43, which is Average. Amneal Pharmaceuticals, Inc. has a Quality Score of 79, which is Strong.

The Quality Grade Winner: Amneal Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Amneal Pharmaceuticals, Inc. has a better overall quality grade than Hims & Hers Health, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc. Grades

In addition to Growth, Value and Quality, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Hims & Hers Health, Inc., Amneal Pharmaceuticals or Inc. Stock?

Overall, Hims & Hers Health, Inc. stock has a Value Score of 8, Growth Score of 37 and Quality Score of 43.

Amneal Pharmaceuticals, Inc. stock has a Value Score of 36, Growth Score of 100 and Quality Score of 79.

Comparing Hims & Hers Health, Inc., Amneal Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.